FDA to review GSK’s Nucala for COPD
The US FDA has accepted a submission from GSK to review a new indication of Nucala (mepolizumab) as an add-on maintenance treatment for COPD.
The US FDA has accepted a submission from GSK to review a new indication of Nucala (mepolizumab) as an add-on maintenance treatment for COPD.
What's Your Reaction?
